fomesafen has been researched along with Mitochondrial Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krishnamurthy, S; Kumar, A; Narayan, G; Samaiya, PK | 1 |
| Stewart Coats, AJ | 1 |
2 other study(ies) available for fomesafen and Mitochondrial Diseases
| Article | Year |
|---|---|
Tempol (4 hydroxy-tempo) inhibits anoxia-induced progression of mitochondrial dysfunction and associated neurobehavioral impairment in neonatal rats.
Topics: Animals; Animals, Newborn; Antioxidants; Apoptosis; Catalase; Cyclic N-Oxides; Cytochromes c; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Hypoxia; Membrane Potential, Mitochondrial; Mitochondrial Diseases; Muscle Strength; NADH Dehydrogenase; Nitric Oxide; Proto-Oncogene Proteins c-bcl-2; Rats; Reflex; Spin Labels; Succinate Dehydrogenase; Superoxide Dismutase | 2017 |
The muscle hypothesis revisited.
Topics: Heart Diseases; Humans; Mitochondrial Diseases; Muscular Diseases; Reflex | 2017 |